NCT04347473RecruitingPhase 4
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.
Source: ClinicalTrials.gov · Last updated 15 Apr 2020 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 13 Apr 2020
- Start date
- 6 Apr 2020
- Primary completion date
- 30 Dec 2020
- Lead sponsor
- Psoriasis Treatment Center of Central New Jersey
- Diseases
- Psoriasis
- NCT number
- NCT04347473
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 25
- From 6 Apr 2020 to the primary completion date, 30 Dec 2020
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of significant uncontrolled medical condition that in the opinion of the investigator would affect patient safety during the trial.
- Active or untreated latent tuberculosis (TB)
Other
- Non-plaque forms of psoriasis
- Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating
Who the study is looking for
- Male or female adult ≥ 18 years of age;
- Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by
- BSA 10%
- PGA ≥3
- PASI ≥12
- Must be a candidate for phototherapy and/or systemic therapy
- Females of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Psoriasis Treatment Center of Central New Jersey Coordinator of this site? Confirm its status | East Windsor | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.